Bertwistle D, D'Yachkova Y, Vickers AD, Hawe E, Fernandez M, Drove N, Lorenzo M, Wolowacz S. Comparative efficacy and saftey of interventions in the treatment of advanced soft tissue sarcoma: a systematic review and network meta analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A712.
Boysen M, Tyas D, Ling C, Wolowacz S. The new NICE cancer drugs fund technology appraisal process: your questions answered. Presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria.
Muszbek N, Wolowacz S, Benedict A. Health economic modeling in oncology. Presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria.
Wolowacz S, Briggs A, Lloyd AJ, Doward L. Collecting health-state utility estimates for economic models in clinical studies. Presented at the 2016 ISPOR 19th Annual European Congress; October 29, 2016. Vienna, Austria.
Wolowacz S, ISPOR Task Force. Response to editorial: estimating health-state utility for economic models in clinical studies: An ISPOR good research practices task force report. Value Health. 2016 Sep;19(6):702-3. doi: 10.1016/j.jval.2016.08.728
Wolowacz SE. Task force recommendations on the collection of health-state utility data in clinical studies: an interview with Sorrel E. Wolowacz, PhD, Co-Chair, on good practices for Outcomes Research Task Force. Value & outcomes spotlight. 2016 Sep;2(5):22-3.
Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, Lloyd A, Norman R. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016 Sep;19(2016):704-19. doi: 10.1016/j.jval.2016.06.001
Herring W, Pearson I, Purser M, Nakhaipour HR, Haiderali A, Wolowacz S, Jayasundara K. Cost effectiveness of ofatumumab plus chlorambucil in first-line chronic lymphocytic leukaemia in Canada. Pharmacoeconomics. 2016 Jan;34(1):77-90. doi: 10.1007/s40273-01509332-5